Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.